Pharmaceutical News

RSS

Existing compound offers hope for slowing Huntington's disease progression

Currently, there is no treatment to halt the progression of Huntington's disease (HD), a fatal genetic disorder that slowly robs sufferers of their physical and mental abilities. Now, researchers at University of California, San Diego School of Medicine have discovered that an existing compound, previously tested for diabetes, offers hope for slowing HD and its symptoms.

8 Dec 2015

Researchers discover 'triple attack' technique to target liver cancer tumors

In an interdisciplinary collaboration between prominent academic and industry investigators, researchers have discovered a novel method for repositioning an FDA-approved anti-cancer compound so it can specifically target liver cancer tumors. A 'triple attack' technique combining chemotherapy, thermal ablation, and hyperthermia provided a highly targeted, yet minimally invasive approach.

8 Dec 2015

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

The Dompé biopharmaceutical company announced today that the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) has officially designated recombinant human Nerve Growth Factor (rhNGF) - the investigational biotech molecule developed by Dompé based on research by Nobel Laureate Rita Levi Montalcini - as an orphan drug for the treatment of neurotrophic keratitis.

8 Dec 2015

BioAtla, Pfizer sign license and option agreement for new class of antibody therapeutics

BioAtla LLC, a biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics, today announced that it has entered into a license and option agreement with Pfizer Inc. to advance the development and commercialization of a new class of antibody therapeutics based on BioAtla's CAB platform and utilizing Pfizer's proprietary antibody drug conjugate (ADC) payloads.

8 Dec 2015

FDA clears use of XSTAT 30 wound dressing to control severe bleeding in civilian population

Today, the U.S. Food and Drug Administration cleared the use of the XSTAT 30 wound dressing, an expandable, multi-sponge dressing used to control severe, life-threatening bleeding from wounds in areas that a tourniquet cannot be placed (such as the groin or armpit) in battlefield and civilian trauma settings.

8 Dec 2015

Gallstones, statins increase risk of acute pancreatitis, shows study

Idiopathic pancreatitis is often caused by small gallstones that are difficult to observe prior to surgery, shows a study from the University of Eastern Finland. Small gallstones were found in surgery from two out of three idiopathic pancreatitis patients.

8 Dec 2015

Lancet study compares prices of new cancer drugs in high-income countries

The price of new cancer drugs varies widely (from 28% to 388%) between high-income countries in Europe, Australia, and New Zealand, new research published in The Lancet Oncology has found.

8 Dec 2015

Children suffering from neuroblastoma may benefit from potential new treatment

Children suffering from a cancer of the nervous system could benefit from a potential new treatment, thanks to an international team led by researchers at the University of Kent and at the Institute of Medical Virology at the Goethe-University, Frankfurt am Main, Germany.

7 Dec 2015

Yale researchers develop vaccine strategy that reduces risk of flu in cancer patients

Yale Cancer Center researchers have developed a vaccine strategy that reduces the risk of flu infections in cancer patients at highest risk for influenza. The findings were presented Dec. 6 at the 57th annual meeting of the American Society of Hematology in Orlando, Florida.

7 Dec 2015

PAREXEL introduces IMPACT Express Clinical Trial Management System for biopharmaceutical companies

PAREXEL International Corporation, a leading global biopharmaceutical services provider, today introduced IMPACT Express Clinical Trial Management System (CTMS).

7 Dec 2015

Prophylactic antibiotics reduce risk of serious bacterial infections in children with ALL

Prophylactic antibiotics significantly reduce the risk of serious bacterial infections in children during the critical first month of treatment for acute lymphoblastic leukemia (ALL), the most common childhood cancer, according to a U.S. and Canadian study led by investigators from Dana-Farber/Boston Children's Cancer and Blood Disorders Center.

7 Dec 2015

Researchers develop novel computational approach to accelerate search for hepatitis C vaccine

Borrowing from several statistical science models, an interdisciplinary team of researchers from the University of Illinois at Urbana-Champaign has developed a novel computational approach for massively accelerating the search for a hepatitis C vaccine.

1 Dec 2015

Combination therapy increases estrogen receptor positive breast cancer risk in African American women

Postmenopausal African American women who use female hormone supplements containing estrogen and progestin ("combination" therapy) are at an increased risk for estrogen receptor positive breast cancer.

1 Dec 2015

Innovative compound with anti-MRSA qualities may help develop new class of antibiotics

With global health services increasingly worried about the rise of antibiotic resistant diseases, researchers at Maynooth University have discovered a compound whose anti-MRSA qualities pave the way for the development of a new class of antibiotics.

1 Dec 2015

FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

Today the U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications.

30 Nov 2015

Heptares announces strategic drug discovery collaboration with Pfizer

Heptares Therapeutics, the clinical-stage GPCR structure-guided drug discovery and development company and wholly-owned subsidiary of Sosei Group Corporation, announces that it has entered into a strategic drug discovery collaboration with Pfizer Inc. to research and develop potential new medicines directed at up to 10 G protein-coupled receptor (GPCR) targets across multiple therapeutic areas.

30 Nov 2015

Helsinn one step closer to bringing anamorelin HCI to market for treatment of anorexia, cachexia in NSCLC patients

Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announced that the European Medicines Agency accepted for review, the marketing authorization application (MAA) for anamorelin HCI, a novel, orally active selective ghrelin receptor agonist under development for the treatment of anorexia, cachexia, or unintended weight loss in non-small cell lung cancer (NSCLC) patients.

30 Nov 2015

Testosterone treatment can benefit men with Type 2 diabetes

Men with Type 2 diabetes who have low testosterone levels can benefit significantly from testosterone treatment.

30 Nov 2015

Can-Fite BioPharma reports financial results, provides updates on drug development programs

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs being developed to treat inflammatory diseases, cancer and sexual dysfunction, today reported financial results for the nine months ended September 30, 2015 and updates on its drug development programs.

27 Nov 2015

MOAS launches campaign to raise funds for three upcoming rescue missions at sea

Search and rescue charity Migrant Offshore Aid Station is raising funds this winter for three upcoming missions to mitigate loss of life at sea.

27 Nov 2015

Pharmaceutical News

Existing compound offers hope for slowing Huntington's disease progression

Researchers discover 'triple attack' technique to target liver cancer tumors

Dompé’s investigational biotech molecule receives orphan drug designation for treatment of neurotrophic keratitis

BioAtla, Pfizer sign license and option agreement for new class of antibody therapeutics

FDA clears use of XSTAT 30 wound dressing to control severe bleeding in civilian population

Gallstones, statins increase risk of acute pancreatitis, shows study

Lancet study compares prices of new cancer drugs in high-income countries

Children suffering from neuroblastoma may benefit from potential new treatment

Yale researchers develop vaccine strategy that reduces risk of flu in cancer patients

PAREXEL introduces IMPACT Express Clinical Trial Management System for biopharmaceutical companies

Prophylactic antibiotics reduce risk of serious bacterial infections in children with ALL

Researchers develop novel computational approach to accelerate search for hepatitis C vaccine

Combination therapy increases estrogen receptor positive breast cancer risk in African American women

Innovative compound with anti-MRSA qualities may help develop new class of antibiotics

FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

Heptares announces strategic drug discovery collaboration with Pfizer

Helsinn one step closer to bringing anamorelin HCI to market for treatment of anorexia, cachexia in NSCLC patients

Testosterone treatment can benefit men with Type 2 diabetes

Can-Fite BioPharma reports financial results, provides updates on drug development programs

MOAS launches campaign to raise funds for three upcoming rescue missions at sea

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News